Bacainn Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- 1
- Market Cap
- -
A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BT051 100mgDrug: BT051 300mgDrug: BT051 700mgDrug: BT051 1500mgDrug: BT051 3500mgDrug: Matching Placebo
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Bacainn Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05103878
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath